Trial Profile

Leukemia SPORE Phase II Randomized Study of Decitabine Versus Decitabine and Carboplatin Versus Decitabine and Arsenic in Relapsed, Refractory and Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 27 Mar 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Arsenic trioxide (Primary) ; Carboplatin (Primary) ; Decitabine (Primary)
Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
Focus Therapeutic Use

15 Jan 2016 New trial record
08 Dec 2015 Results (n=42) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com